Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HRD HER2L metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial - Harbeck, N; Fasching, PA; Wuerstlein, R (Ann Oncol, 2023)